𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Biodistribution and Intraoperative Evaluation of Radiolabeled Monoclonal Antibody MX 35 in Patients with Epithelial Ovarian Cancer

✍ Scribed by Stephen C. Rubin; Lale Kostakoglu; Chaitanya Divgi; Mark G. Federici; Connie L. Finstad; Kenneth O. Lloyd; Steven M. Larson; William J. Hoskins

Book ID
115615961
Publisher
Elsevier Science
Year
1993
Tongue
English
Weight
353 KB
Volume
51
Category
Article
ISSN
0090-8258

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Biodistribution of a monoclonal antibody
Biodistribution of a monoclonal antibody-methotrexate conjugate (791T/36-MTX) in patients with colorectal cancer
✍ K. C. Ballantyne; A. C. Perkins; M. V. Pimm; M. C. Garnett; Jane A. Clegg; N. C. πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 French βš– 547 KB

The monoclonal antibody (MAb) 791T/36 which has previously been shown to localise in colorectal cancer has been conjugated to methotrexate (MTX) for potential use as a chemotherapeutic agent in malignant disease. To examine its biodistribution and tumour localisation, 16 patients with primary colore

Antibody-antigen complex formation follo
Antibody-antigen complex formation following injection of OC125 monoclonal antibody in patients with ovarian cancer
✍ Hidde J. Haisma; Anne Battaile; Earl W. Stradtman; Robert C. Knapp; Vincent R. Z πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 French βš– 553 KB

Monoclonal antibody (MAb) O C 125 binds to approximately 80% of epithelial ovarian cancers. Serum antigen, CAI25, can be detected in these patients. "'I-OC 125-F(ab')2 was injected into 5 ovarian carcinoma patients with preinjection serum levels of I50 to 9,000 CAI25 U/ml. Patients received the anti

Induction of IgG antibodies to MUC1 and
Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer
✍ AngΓ¨le L.M. Oei; MarΓ­a Moreno; RenΓ© H.M. Verheijen; Fred C.G.J. Sweep; Chris M.G πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 French βš– 232 KB πŸ‘ 1 views

## Abstract We investigated whether epithelial ovarian cancer patients participating in a randomized phase III trial comparing single intraperitoneal (IP) administration of yttrium‐90‐labeled murine HMFG1 (^90^Y‐muHMFG1) plus standard treatment (AT) __vs.__ standard treatment (ST) alone developed I